These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26657087)

  • 1. Extensions of indication throughout the drug product lifecycle: a quantitative analysis.
    Langedijk J; Whitehead CJ; Slijkerman DS; Leufkens HG; Schutjens MH; Mantel-Teeuwisse AK
    Drug Discov Today; 2016 Feb; 21(2):348-55. PubMed ID: 26657087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
    Mulder J; Verjans R; Verbaanderd C; Pean E; Weemers J; Leufkens HGM; Pignatti F; de Boer A; Voest EE; Stoyanova-Beninska VV; Pasmooij AMG
    Front Med (Lausanne); 2021; 8():790782. PubMed ID: 34957158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
    Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
    Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.
    Ehmann F; Papaluca M; Di Giuseppe F; Pani L; Eskova A; Manolis E; Herold R
    Expert Opin Pharmacother; 2015 Apr; 16(6):903-11. PubMed ID: 25773468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
    Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After thalidomide - do we have the right balance between public health and intellectual property.
    Feldschreiber P; Breckenridge A
    Rev Recent Clin Trials; 2015; 10(1):15-8. PubMed ID: 25925884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
    Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
    Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defeat of antipiracy treaty is hailed as victory for generic drugs.
    Moszynski P
    BMJ; 2012 Jul; 345():e4660. PubMed ID: 22777031
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government.
    van der Pol KH; Aljofan M; Blin O; Cornel JH; Rongen GA; Woestelandt AG; Spedding M
    Appl Health Econ Health Policy; 2023 Nov; 21(6):831-840. PubMed ID: 37398987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
    Childs DW
    Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
    [No Abstract]   [Full Text] [Related]  

  • 20. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.